| Name | Title | Contact Details |
|---|
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents.
TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.
Elk Hill enables children and families to transform overwhelming challenges into successful futures by offering behvioral health and education services.
Quantum Genomics is a biopharmaceutical company specializing in the development of a new drug class for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure.
ChemBridge, Corp. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.